Search results
Where Is Amgen Headed After the Stock Surges on Obesity Drug News?
TheStreet.com· 1 day agoThe company also "tweaked" their forward guidance and the stock was raised to a fundamental...
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Zacks via Yahoo Finance· 1 day agoAmgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged"...
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 11 hours agoGlobal Reach and Market Share: With a presence in over 100 countries, Amgen Inc has established a significant global footprint. Its leading products,...
What's in the Cards for Amgen (AMGN) This Earnings Season?
Zacks· 5 days agoFree Report) will report first-quarter 2024 results on May 2, before market open. Amgen’s product sales are expected to be the lowest in the first quarter per historical trends due to the impact ...
Amgen shares jump after teasing ‘encouraging’ weight loss data
KFGO· 1 day ago(Reuters) - U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company...
Amgen 'encouraged' by weight-loss drug interim data, shares jump
Reuters via AOL· 2 days ago(Reuters) -Amgen on Thursday said it was very encouraged after completing an interim analysis of its...
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
The Record Gazette· 2 days agoAmgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through ...
Analyst Report: Amgen Inc.
Morningstar Research via Yahoo Finance· 1 day agoAmgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel ...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 3 days agoVyndaqel family sales beat the Zacks Consensus Estimate of $952.0 million as well as our model...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoPrevnar sales inched 2% ahead to $6.44 billion. But other key products saw downfalls. Revenue from...
